ASP Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on June 27, 2022. The total number of shares represented in person or by proxy at the meeting was 6,923,589, representing 89.83% of the total issued and outstanding Acerus shares.

Election of Directors

The seven (7) candidates nominated for election to the Acerus board of directors and listed in Acerus’ management information circular dated May 9, 2022, were elected by a majority of the votes cast by shareholders present in person or represented by proxy at the meeting. The voting results are as follows:

Name	Votes For (%)	Votes Withheld (%)
Ian O. Ihnatowycz	6,895,681 (99.85%)	10,296 (0.15%)
Geoff Cotton	6,892,290 (99.80%)	13,687 (0.20%)
Borys Chabursky	6,894,424 (99.83%)	11,553 (0.17%)
Stephen Gregory	6,894,576 (99.84%)	11,401 (0.17%)
Samuel Herschkowitz	6,895,878 (99.85%)	10,099 (0.15%)
Scott Leckie	6,893,526 (99.82%)	12,451 (0.18%)
Edward Gudaitis	6,895,731 (99.85%)	10,246 (0.15%)

Appointment of Auditors

Acerus announced today that its shareholders have approved the re‐appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the fields of urology and men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice regarding forward‐looking statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 14, 2022 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Company Contactir@aceruspharma.com

Investor Relations ContactChris WittyAcerus Investor Relations (646) 438-9385cwitty@darrowir.com